['amyotrophic lateral sclerosis']
['np001', 'placebo']

        Key Inclusion Criteria:

          -  Diagnosis of clinically possible, clinically probable (with or without laboratory
             support), or clinically definite ALS (using the revised El Escorial Criteria)

          -  Forced vital capacity greater than or equal to 65% of that predicted for age and
             height

          -  Onset of ALS-related weakness less than 3 years prior to first dose of study drug

          -  Plasma high sensitivity C-reactive protein (hs-CRP) concentration of greater than or
             equal to 0.113 mg/dL at pre-screening/screening

          -  Stable dose (greater than 30 days) of riluzole if undergoing treatment with this agent

          -  For females: Not be of childbearing potential or agree to use adequate birth control
             during the study

        Key Exclusion Criteria:

          -  Life expectancy of less than 6 months

          -  Tracheotomy or be using ventilatory assistance, including Bi-level Positive Airway
             Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)

          -  Active pulmonary disease

          -  Gastrostomy

          -  Stem cell therapy

          -  Immune modulator therapy or participation in studies of other agents within 12 weeks
             of pre-screening/screening

          -  Unstable medical condition other than ALS
      